A B2B event designed to connect Drug Discovery Experts, Biotech Innovation, and emerging technologies. This expert-led, two-day event blends keynotes, case studies, panel discussions, and 1:1 meetings to turn research into real-world impact.For any queries, reach out to Tina Aston at ta@worldbigroup.comRelated Post: Clinical Trials Operations DACH 2025 | Sep 18 | Basel,…
Philippe Barillon joins PharmaShots Managing Editor Himanshu Sehgal for an enlightening dialogue exchange in a Pre-Conference Talk.Philippe will be joining the upcoming Reuters Events Pharma 2025 as a panelist for the topic “Bridging gaps: Leverage data, tech and RWE for enhanced healthcare access and market growth”.Philippe highlights the potential applications of RWEs using…
Vikram Mohan will be joining the upcoming Pharma 2025 event as a panelist with the Topic “Content’s Industrial Revolution”. Vikram believes that with a paradigm shift from the traditional approach to creating, approving, reviewing, and deploying content in the evolving biopharma industry, there’s room for generative AI to act as an assistant to make the…
Brimming with insightful panel discussions, presentations on disruptive technologies, and illuminating real-world evidence shaping the healthcare landscape now and then, the two-day Reuters event celebrated pharmaceutical innovation and fresh perspectives pouring into the interactive sessions.In the panel discussion at Reuters Pharma USA 2025, Rahul Mittal outlined ways to enhance patient centricity and engagement. Rahul…
CAR T-cell therapies hold a promising foothold in addressing unmet healthcare needs. Arcellx, a clinical-stage biotech company, is steadfastly exploring the potential of cell therapy in RRMM and generalized myasthenia gravis patients with its lead asset anito-cel.
During presentations at ASH, anito-cel demonstrated no delayed neurotoxicity in both P-1 and pivotal P-II clinical trials for multiple myeloma.…

